Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MedinCell
Pharma
Teva and MedinCell's long-acting schizophrenia med wins in phase 3
The companies formulated a long-acting version of popular antipsychotic olanzapine, which Eli Lilly first marketed in the 90s.
Zoey Becker
May 8, 2024 10:40am
Medincell, AbbVie set out to create new long-acting injectables
Apr 17, 2024 2:49pm
FDA approves Teva, MedinCell's long-acting schizophrenia therapy
May 1, 2023 9:30am
Teva takes 2nd long-acting schizophrenia drug into phase 3
Jan 31, 2023 7:10am
Teva partner bags $42M loan for long-acting injectable R&D
Nov 29, 2022 10:25am
Teva refiles long-acting schizophrenia drug after FDA rejection
Nov 8, 2022 7:20am
